SlideShare uma empresa Scribd logo
1 de 30
Baixar para ler offline
Antinauseants & Antiemetic
         Agents
    Brian J. Piper, Ph.D., M.S.




                   October 16, 2012
Learning objectives
Pharmacy students should be able to:
1. Explain emesis pathway(s)
2. Identify drug targets for antiemetic agents
3. Describe mechanism of action of antiemetic agents
4. Recognize adverse effects of antiemetic agents




                    Ibn Bultan (1531)
Emesis
• A protective reflex that serves to rid the stomach
  and intestine of toxic substances and prevent their
  further ingestion.

• Vomiting is a complex process that consists of:
   – Pre-ejection phase: gastric relaxation & retroperistalsis
   – Retching: rhythmic action of respiratory muscles
     preceding vomiting and consisting of contraction of
     abdominal and intercostal muscles and diaphragm against
     a closed glottis
   – Ejection: intense contraction of the abdominal muscles
     and relaxation of the upper esophageal sphincter
Importance
• Vomiting is an adverse effect of many clinically
  useful drugs:
  – cancer chemotherapy & radiation
  – opioids
  – general anesthetics
• Nausea may be a component of:
  – migraines
  – pregnancy
Area Postrema
  • surrounds 4th ventricle
  • outside blood brain barrier & monitors blood




Miller & Leslie (1994). Frontiers in Neuroendocrinology, 15(4), 301-320.
Activity of Area Postrema Following
                   Chemotherapy




Neuronal activation (c-fos, arrowheads) in the area postrema (AP)
following cisplatin administration (10 mg/kg) to an adult ferret. CC:
Central Canal (4th ventricle); NTS: nucleus of the solitary tract; DMX
dorsal motor nucleus of vagus nerve.

Miller & Leslie (1994). Frontiers in Neuroendocrinology, 15(4), 301-320.
Area Postrema & Nausea




 • Rats (non-retching) got saccharine, injection (saline or lithium chloride), then
   two-bottle choice




Bernstein et al. (1992). Brain Research, 575, 132-137.
Area Postrema & Nausea




• Rats (non-retching) got saccharine, injection (saline or lithium chloride), then
  two-bottle choice
• Lesion of the area postrema eliminated this response.




Bernstein et al. (1992). Brain Research, 575, 132-137.
Area Postrema (AP) & Nausea
                                                                       *
                                *




•   Rats (+AP lesioned) got saccharine, injection (saline or lithium chloride)
•   Behavioral ratings of response to lithium (Lieing on Belly) were made
•   Pre-inections, a meal was consumed. Stomach contents were examined.
•   Area Postrema = chemoreceptor trigger zone


Bernstein et al. (1992). Brain Research, 575, 132-137.
Anatomy of Emesis
• Chemoreceptor trigger zone (CTZ) in the area postrema
  (AP) at the bottom of the fourth ventricle has high
  concentration of:
  •   5-HT3 (?)
  •   D2
  •   M1
  •   NK1
  •   opioid
• The CTZ has connections to the Nucleus of the Tractus
  Solitarius (NTS) & Reticular Formation (aka vomiting
  center) which contains:
  • 5-HT3 (?)
  • M1
  • NK1
M1




                                                                     D2




Krakauer et al. (2005). New England Journal of Medicine, 352, 817.
Classification of antiemetics




† some peripheral activity at 5-HT3 receptor;
‡ some antihistamine and anticholinergic activity
Ondansetron
• MOA: 5-HT3 antagonist
• Indications:
  radiation, chemotherapy, postoperapative
• Dosing: 1x/day
• Adverse Effects: constipation & headache
5-HT3 Antagonists (-etron) Compared
                        Granisetron            Ondansetron      Dolasetron




Brand name              Kytril, Sancuso        Zofran           Anzemet
FDA Approval            1988                   1991G            1997
Indications             chemotherapy           chemotherapy     chemotherapy
                        radiation              radiation        radiation
Half-life (hours)       9                      4                8
Routes of               oral, iv, transdermal oral, iv          oral, iv
administration
Adverse effects         constipation &         constipation &   headache
                        headaches              headaches        tachy/bradycardia

Ggeneric   form available
5-HT3 Antagonists (-etron) Compared
                    Granisetron           Ondansetron      Palonosetron




Brand name          Kytril, Sancuso       Zofran           Aloxi
FDA Approval        1988                  1991G            2003 (delayed nausea)
Indications         chemotherapy          chemotherapy     chemotherapy
                    radiation             radiation        post-operative
Half-life (hours)   10                    4                40
Routes of           oral, iv, transderm   oral, iv         oral, iv
administration
Adverse effects     constipation &        constipation &   headache, constipation,
                    headaches             headaches        QT
5-HT3 Antagonists Compared: Efficacy
 • Chemotherapy patients (N = 563) randomized to
   receive ondansetron versus palonosetron
 • Treatment failure = emetic response or rescue
   medication


                                             % of Patients




Gralla et al. (2003). Annals of Oncology, 14, 1570-1577.
5-HT3 Antagonists Compared: Safety
 • Chemotherapy patients (N = 563) randomized to
   receive ondansetron versus palonosetron




Gralla et al. (2003). Annals of Oncology, 14, 1570-1577.
Pathway of Emesis

     4
                3
      1

5




            2
Pavlov’s Experiments
During conditioning, the neutral stimulus (tone)
and the US (food) are paired, resulting in
salivation (UR).
After conditioning, the neutral stimulus (now
Conditioned Stimulus, CS) elicits salivation (now
Conditioned Response, CR)




                                                    19
Classical Conditioning & Nausea
• Pre-Conditioning
  – Neutral Stimulus: hospital environment
  – Unconditioned Stimulus: chemotherapy
  – Unconditioned Response: nausea & vomiting
• Post-Conditioning
  – Conditioned Stimulus: hospital environment
  – Conditioned Response: nausea & vomiting
Metoclopramide
• MOA: D2 antagonist, 5-HT3 antagonist
• Indications: chemotherapy, post-operative
• Adverse Effects: restlessness, Parkinsonian
  symptoms


1 min: http://www.youtube.com/watch?v=dum81RdFrhM
Pronunciation: http://dictionary.reference.com/browse/metoclopramide?s=t
Olanzapine
• MOA: D2 antagonist + others
• Indications: acute & delayed CINV
• Adverse Effects:




                     Stahl (2008). Essential Psychopharmacology, p. 411.
Dronabinol
•   Synthetic delta-9-tetrahydrocannabinol (Δ9-THC)
•   Schedule: III
•   MOA: Cannabinoid receptors?
•   AE: dysphoria, postural hypotension
Density of Cannabinoid Receptor 1 (Increased
 Darkness = more receptors labeled with [3H]CP-55,940)




                                     Hekenham et al. (1991) J Neurosci, 11, 563-583.
Aprepitant
MOA:
 substance P binds to NeurokininA receptors
  Arg-Pro-Lys-Pro-Gln-Gln-Phe-Phe-Gly-Leu-Met
  NeurokininA antagonist
Indications: CINV, PONV
Adverse Effects: asthenia, constipation, hiccups
NeurokininA Antagonist: Efficacy
 • Abdominal surgery patients (N=750) randomized
   to receive oral Aprepitant or Ondansetron
 • Hours until vomiting or rescue medication




Gan et al. (2007). Anesthesia & Analgesia, 104(5), 1082-1089.
NeurokininA Antagonist: Safety
 • Abdominal surgery patients (N=750) randomized
   to receive oral Aprepitant or Ondansetron




Gan et al. (2007). Anesthesia & Analgesia, 104(5), 1082-1089.
Summary
   • High Therapeutic Index                   • Low Therapeutic Index
       – 5-HT3 antagonists                        – cannabinoids
       – NK1 antagonists                          – dopamine antagonists
       – corticosteroids (combo)                  – benzodiazepines




Hesketh (2008). New England Journal of Medicine, 358, 2482-2494.
Abbreviations
CB1    Cannabinoid 1
CINV   Chemotherapy-induced nausea and vomiting
CTZ    Chemoreceptor trigger zone
DA     Dopamine
NK1    Neurokinin 1
PONV   Post-operative nausea and vomiting
STN    Solitary tract nucleus
VC     Vomiting center

Mais conteúdo relacionado

Mais procurados (20)

Antiepileptics
AntiepilepticsAntiepileptics
Antiepileptics
 
Seretonin (5HT) and Its Antagonists Pharmacology
Seretonin (5HT) and Its Antagonists PharmacologySeretonin (5HT) and Its Antagonists Pharmacology
Seretonin (5HT) and Its Antagonists Pharmacology
 
Serotonin and anti serotonin drugs
Serotonin and anti serotonin drugsSerotonin and anti serotonin drugs
Serotonin and anti serotonin drugs
 
Antiemetic
AntiemeticAntiemetic
Antiemetic
 
Antiemetics
AntiemeticsAntiemetics
Antiemetics
 
Antiemetics
AntiemeticsAntiemetics
Antiemetics
 
Anti emetics
Anti emeticsAnti emetics
Anti emetics
 
Sympatholytics
SympatholyticsSympatholytics
Sympatholytics
 
Emesis and anti emetic drugs
Emesis and anti emetic drugsEmesis and anti emetic drugs
Emesis and anti emetic drugs
 
Antiemetic drugs
Antiemetic drugsAntiemetic drugs
Antiemetic drugs
 
Sedatives & hypnotics
Sedatives & hypnoticsSedatives & hypnotics
Sedatives & hypnotics
 
Pharmacotherapy of Parkinson’s disease
Pharmacotherapy of Parkinson’s diseasePharmacotherapy of Parkinson’s disease
Pharmacotherapy of Parkinson’s disease
 
Emetics ,antiemetics, prokinetics
Emetics ,antiemetics, prokineticsEmetics ,antiemetics, prokinetics
Emetics ,antiemetics, prokinetics
 
Serotonin & Their antagonists
Serotonin & Their antagonistsSerotonin & Their antagonists
Serotonin & Their antagonists
 
Antiemetics
AntiemeticsAntiemetics
Antiemetics
 
Opioid
OpioidOpioid
Opioid
 
Serotonin
SerotoninSerotonin
Serotonin
 
Dopamine
DopamineDopamine
Dopamine
 
Antipsychotics
AntipsychoticsAntipsychotics
Antipsychotics
 
CNS stimulants and cognition enhancers
CNS stimulants and cognition enhancersCNS stimulants and cognition enhancers
CNS stimulants and cognition enhancers
 

Semelhante a Antiemetics

Anti emetics 1.ppt
Anti emetics 1.pptAnti emetics 1.ppt
Anti emetics 1.pptssuser7b172e
 
2- Antiemetic.ppt
2- Antiemetic.ppt2- Antiemetic.ppt
2- Antiemetic.pptHananHagar
 
Emetics and anti emetics
Emetics and anti emeticsEmetics and anti emetics
Emetics and anti emeticsSanthaLakshmi12
 
ANTIEMETICS AND PROKINETICS.pptx
ANTIEMETICS AND PROKINETICS.pptxANTIEMETICS AND PROKINETICS.pptx
ANTIEMETICS AND PROKINETICS.pptxKarthiga M
 
General and local anesthesia
General and local anesthesiaGeneral and local anesthesia
General and local anesthesiajonathan kiprop
 
123455NAUSEA _ VOMITING LECTURE NOTES.pptx
123455NAUSEA _ VOMITING LECTURE NOTES.pptx123455NAUSEA _ VOMITING LECTURE NOTES.pptx
123455NAUSEA _ VOMITING LECTURE NOTES.pptxabwonekenneth1
 
Emetcs and antiemetics
Emetcs and antiemeticsEmetcs and antiemetics
Emetcs and antiemeticsChintan Doshi
 
Msne 5356 adv pharma ondansetron 19 nov 2016 final
Msne 5356 adv pharma ondansetron 19 nov 2016 finalMsne 5356 adv pharma ondansetron 19 nov 2016 final
Msne 5356 adv pharma ondansetron 19 nov 2016 finalwilfredoebreomaan
 
chemotherapy induced Nausea &vomiting
chemotherapy induced Nausea &vomitingchemotherapy induced Nausea &vomiting
chemotherapy induced Nausea &vomitingMostafa Hanafi
 
Part 2 autonomic.pptx
Part 2 autonomic.pptxPart 2 autonomic.pptx
Part 2 autonomic.pptxSaniaBangura
 
Antiemetics, Pharmacology by Baqir Naqvi.pptx
Antiemetics, Pharmacology  by Baqir Naqvi.pptxAntiemetics, Pharmacology  by Baqir Naqvi.pptx
Antiemetics, Pharmacology by Baqir Naqvi.pptxDr. Baqir Raza Naqvi
 
ICU analgesia
ICU analgesiaICU analgesia
ICU analgesiapbsherren
 
Asthma_Medication.pdf
Asthma_Medication.pdfAsthma_Medication.pdf
Asthma_Medication.pdfRutvikShah52
 

Semelhante a Antiemetics (20)

Anti emetics 1.ppt
Anti emetics 1.pptAnti emetics 1.ppt
Anti emetics 1.ppt
 
2- Antiemetic.ppt
2- Antiemetic.ppt2- Antiemetic.ppt
2- Antiemetic.ppt
 
Ponv anaesthesia managment
Ponv anaesthesia managmentPonv anaesthesia managment
Ponv anaesthesia managment
 
Emetics and anti emetics
Emetics and anti emeticsEmetics and anti emetics
Emetics and anti emetics
 
ANTIEMETICS AND PROKINETICS.pptx
ANTIEMETICS AND PROKINETICS.pptxANTIEMETICS AND PROKINETICS.pptx
ANTIEMETICS AND PROKINETICS.pptx
 
General and local anesthesia
General and local anesthesiaGeneral and local anesthesia
General and local anesthesia
 
Antiemetic drugs
Antiemetic drugs Antiemetic drugs
Antiemetic drugs
 
Emesis /CINV
Emesis /CINVEmesis /CINV
Emesis /CINV
 
123455NAUSEA _ VOMITING LECTURE NOTES.pptx
123455NAUSEA _ VOMITING LECTURE NOTES.pptx123455NAUSEA _ VOMITING LECTURE NOTES.pptx
123455NAUSEA _ VOMITING LECTURE NOTES.pptx
 
Emetcs and antiemetics
Emetcs and antiemeticsEmetcs and antiemetics
Emetcs and antiemetics
 
Msne 5356 adv pharma ondansetron 19 nov 2016 final
Msne 5356 adv pharma ondansetron 19 nov 2016 finalMsne 5356 adv pharma ondansetron 19 nov 2016 final
Msne 5356 adv pharma ondansetron 19 nov 2016 final
 
Antiemetics, emetics
Antiemetics, emeticsAntiemetics, emetics
Antiemetics, emetics
 
chemotherapy induced Nausea &vomiting
chemotherapy induced Nausea &vomitingchemotherapy induced Nausea &vomiting
chemotherapy induced Nausea &vomiting
 
Part 2 autonomic.pptx
Part 2 autonomic.pptxPart 2 autonomic.pptx
Part 2 autonomic.pptx
 
Antiemetics, Pharmacology by Baqir Naqvi.pptx
Antiemetics, Pharmacology  by Baqir Naqvi.pptxAntiemetics, Pharmacology  by Baqir Naqvi.pptx
Antiemetics, Pharmacology by Baqir Naqvi.pptx
 
Serotonin 5
Serotonin 5Serotonin 5
Serotonin 5
 
ICU analgesia
ICU analgesiaICU analgesia
ICU analgesia
 
01 antiemetics 1
01 antiemetics 101 antiemetics 1
01 antiemetics 1
 
Ketamine for Oral Use
Ketamine for Oral UseKetamine for Oral Use
Ketamine for Oral Use
 
Asthma_Medication.pdf
Asthma_Medication.pdfAsthma_Medication.pdf
Asthma_Medication.pdf
 

Mais de Brian Piper

Current recreational drugs: RX462 Drug Abuse & Society, Spring 2015 Class pre...
Current recreational drugs: RX462 Drug Abuse & Society, Spring 2015 Class pre...Current recreational drugs: RX462 Drug Abuse & Society, Spring 2015 Class pre...
Current recreational drugs: RX462 Drug Abuse & Society, Spring 2015 Class pre...Brian Piper
 
Drug Abuse & Society (RX 462) Presentations-Spring 2014
Drug Abuse & Society (RX 462) Presentations-Spring 2014Drug Abuse & Society (RX 462) Presentations-Spring 2014
Drug Abuse & Society (RX 462) Presentations-Spring 2014Brian Piper
 
electronic cigarettes
electronic cigaretteselectronic cigarettes
electronic cigarettesBrian Piper
 
Examination of Sexually Dimorphic Behavior on the Novel-Image Novel-Location ...
Examination of Sexually Dimorphic Behavior on the Novel-Image Novel-Location ...Examination of Sexually Dimorphic Behavior on the Novel-Image Novel-Location ...
Examination of Sexually Dimorphic Behavior on the Novel-Image Novel-Location ...Brian Piper
 
Drug abuse and society drug presentations: Spring 2013
Drug abuse and society drug presentations: Spring 2013Drug abuse and society drug presentations: Spring 2013
Drug abuse and society drug presentations: Spring 2013Brian Piper
 
Sedative & Hypnotic Drugs Part II
Sedative & Hypnotic Drugs Part IISedative & Hypnotic Drugs Part II
Sedative & Hypnotic Drugs Part IIBrian Piper
 
Sedative & Hypnotic Agents Part I
Sedative & Hypnotic Agents Part ISedative & Hypnotic Agents Part I
Sedative & Hypnotic Agents Part IBrian Piper
 
Agents for Bipolar
Agents for BipolarAgents for Bipolar
Agents for BipolarBrian Piper
 
Psychopharmacology of Anxiety: Part II OCD & PTSD
Psychopharmacology of Anxiety: Part II OCD & PTSDPsychopharmacology of Anxiety: Part II OCD & PTSD
Psychopharmacology of Anxiety: Part II OCD & PTSDBrian Piper
 
Psychopharmacology of Anxiety Disorders I: GAD & SAD
Psychopharmacology of Anxiety Disorders I: GAD & SADPsychopharmacology of Anxiety Disorders I: GAD & SAD
Psychopharmacology of Anxiety Disorders I: GAD & SADBrian Piper
 
Antipsychotics Part II
Antipsychotics Part IIAntipsychotics Part II
Antipsychotics Part IIBrian Piper
 
Antipsychotics I
Antipsychotics IAntipsychotics I
Antipsychotics IBrian Piper
 
Anti Inflammation agents for CNS
Anti Inflammation agents for CNSAnti Inflammation agents for CNS
Anti Inflammation agents for CNSBrian Piper
 
Antidepressants Part II
Antidepressants Part IIAntidepressants Part II
Antidepressants Part IIBrian Piper
 
Antidepressants Part I
Antidepressants Part IAntidepressants Part I
Antidepressants Part IBrian Piper
 
Anticonvulsants Part II
Anticonvulsants Part IIAnticonvulsants Part II
Anticonvulsants Part IIBrian Piper
 
Anticonvulsants Part I
Anticonvulsants Part IAnticonvulsants Part I
Anticonvulsants Part IBrian Piper
 
Agents for Brain Injury
Agents for Brain InjuryAgents for Brain Injury
Agents for Brain InjuryBrian Piper
 
Pathophysiology: Myasthenia Gravis & Restless Leg Syndrome
Pathophysiology: Myasthenia Gravis & Restless Leg SyndromePathophysiology: Myasthenia Gravis & Restless Leg Syndrome
Pathophysiology: Myasthenia Gravis & Restless Leg SyndromeBrian Piper
 

Mais de Brian Piper (20)

Current recreational drugs: RX462 Drug Abuse & Society, Spring 2015 Class pre...
Current recreational drugs: RX462 Drug Abuse & Society, Spring 2015 Class pre...Current recreational drugs: RX462 Drug Abuse & Society, Spring 2015 Class pre...
Current recreational drugs: RX462 Drug Abuse & Society, Spring 2015 Class pre...
 
Drug Abuse & Society (RX 462) Presentations-Spring 2014
Drug Abuse & Society (RX 462) Presentations-Spring 2014Drug Abuse & Society (RX 462) Presentations-Spring 2014
Drug Abuse & Society (RX 462) Presentations-Spring 2014
 
electronic cigarettes
electronic cigaretteselectronic cigarettes
electronic cigarettes
 
Examination of Sexually Dimorphic Behavior on the Novel-Image Novel-Location ...
Examination of Sexually Dimorphic Behavior on the Novel-Image Novel-Location ...Examination of Sexually Dimorphic Behavior on the Novel-Image Novel-Location ...
Examination of Sexually Dimorphic Behavior on the Novel-Image Novel-Location ...
 
Drug abuse and society drug presentations: Spring 2013
Drug abuse and society drug presentations: Spring 2013Drug abuse and society drug presentations: Spring 2013
Drug abuse and society drug presentations: Spring 2013
 
Sedative & Hypnotic Drugs Part II
Sedative & Hypnotic Drugs Part IISedative & Hypnotic Drugs Part II
Sedative & Hypnotic Drugs Part II
 
Sedative & Hypnotic Agents Part I
Sedative & Hypnotic Agents Part ISedative & Hypnotic Agents Part I
Sedative & Hypnotic Agents Part I
 
Agents for Bipolar
Agents for BipolarAgents for Bipolar
Agents for Bipolar
 
Psychopharmacology of Anxiety: Part II OCD & PTSD
Psychopharmacology of Anxiety: Part II OCD & PTSDPsychopharmacology of Anxiety: Part II OCD & PTSD
Psychopharmacology of Anxiety: Part II OCD & PTSD
 
Psychopharmacology of Anxiety Disorders I: GAD & SAD
Psychopharmacology of Anxiety Disorders I: GAD & SADPsychopharmacology of Anxiety Disorders I: GAD & SAD
Psychopharmacology of Anxiety Disorders I: GAD & SAD
 
Antipsychotics Part II
Antipsychotics Part IIAntipsychotics Part II
Antipsychotics Part II
 
Antipsychotics I
Antipsychotics IAntipsychotics I
Antipsychotics I
 
Anti Inflammation agents for CNS
Anti Inflammation agents for CNSAnti Inflammation agents for CNS
Anti Inflammation agents for CNS
 
Antidepressants Part II
Antidepressants Part IIAntidepressants Part II
Antidepressants Part II
 
Antidepressants Part I
Antidepressants Part IAntidepressants Part I
Antidepressants Part I
 
Anticonvulsants Part II
Anticonvulsants Part IIAnticonvulsants Part II
Anticonvulsants Part II
 
Anticonvulsants Part I
Anticonvulsants Part IAnticonvulsants Part I
Anticonvulsants Part I
 
Agents for Brain Injury
Agents for Brain InjuryAgents for Brain Injury
Agents for Brain Injury
 
ADHD Drugs
ADHD DrugsADHD Drugs
ADHD Drugs
 
Pathophysiology: Myasthenia Gravis & Restless Leg Syndrome
Pathophysiology: Myasthenia Gravis & Restless Leg SyndromePathophysiology: Myasthenia Gravis & Restless Leg Syndrome
Pathophysiology: Myasthenia Gravis & Restless Leg Syndrome
 

Último

Music Therapy's Impact in Palliative Care| IAPCON2024| Dr. Tara Rajendran
Music Therapy's Impact in Palliative Care| IAPCON2024| Dr. Tara RajendranMusic Therapy's Impact in Palliative Care| IAPCON2024| Dr. Tara Rajendran
Music Therapy's Impact in Palliative Care| IAPCON2024| Dr. Tara RajendranTara Rajendran
 
Nutrition of OCD for my Nutritional Neuroscience Class
Nutrition of OCD for my Nutritional Neuroscience ClassNutrition of OCD for my Nutritional Neuroscience Class
Nutrition of OCD for my Nutritional Neuroscience Classmanuelazg2001
 
Radiation Dosimetry Parameters and Isodose Curves.pptx
Radiation Dosimetry Parameters and Isodose Curves.pptxRadiation Dosimetry Parameters and Isodose Curves.pptx
Radiation Dosimetry Parameters and Isodose Curves.pptxDr. Dheeraj Kumar
 
VarSeq 2.6.0: Advancing Pharmacogenomics and Genomic Analysis
VarSeq 2.6.0: Advancing Pharmacogenomics and Genomic AnalysisVarSeq 2.6.0: Advancing Pharmacogenomics and Genomic Analysis
VarSeq 2.6.0: Advancing Pharmacogenomics and Genomic AnalysisGolden Helix
 
PHYSIOTHERAPY IN HEART TRANSPLANTATION..
PHYSIOTHERAPY IN HEART TRANSPLANTATION..PHYSIOTHERAPY IN HEART TRANSPLANTATION..
PHYSIOTHERAPY IN HEART TRANSPLANTATION..AneriPatwari
 
Study on the Impact of FOCUS-PDCA Management Model on the Disinfection Qualit...
Study on the Impact of FOCUS-PDCA Management Model on the Disinfection Qualit...Study on the Impact of FOCUS-PDCA Management Model on the Disinfection Qualit...
Study on the Impact of FOCUS-PDCA Management Model on the Disinfection Qualit...MehranMouzam
 
epilepsy and status epilepticus for undergraduate.pptx
epilepsy and status epilepticus  for undergraduate.pptxepilepsy and status epilepticus  for undergraduate.pptx
epilepsy and status epilepticus for undergraduate.pptxMohamed Rizk Khodair
 
CCSC6142 Week 3 Research ethics - Long Hoang.pdf
CCSC6142 Week 3 Research ethics - Long Hoang.pdfCCSC6142 Week 3 Research ethics - Long Hoang.pdf
CCSC6142 Week 3 Research ethics - Long Hoang.pdfMyThaoAiDoan
 
Phytochemical Investigation of Drugs PDF.pdf
Phytochemical Investigation of Drugs PDF.pdfPhytochemical Investigation of Drugs PDF.pdf
Phytochemical Investigation of Drugs PDF.pdfDivya Kanojiya
 
LESSON PLAN ON fever.pdf child health nursing
LESSON PLAN ON fever.pdf child health nursingLESSON PLAN ON fever.pdf child health nursing
LESSON PLAN ON fever.pdf child health nursingSakthi Kathiravan
 
METHODS OF ACQUIRING KNOWLEDGE IN NURSING.pptx by navdeep kaur
METHODS OF ACQUIRING KNOWLEDGE IN NURSING.pptx by navdeep kaurMETHODS OF ACQUIRING KNOWLEDGE IN NURSING.pptx by navdeep kaur
METHODS OF ACQUIRING KNOWLEDGE IN NURSING.pptx by navdeep kaurNavdeep Kaur
 
Wessex Health Partners Wessex Integrated Care, Population Health, Research & ...
Wessex Health Partners Wessex Integrated Care, Population Health, Research & ...Wessex Health Partners Wessex Integrated Care, Population Health, Research & ...
Wessex Health Partners Wessex Integrated Care, Population Health, Research & ...Wessex Health Partners
 
Myelin Oligodendrocyte Glycoprotein antibody associated disease (MOGAD)
Myelin Oligodendrocyte Glycoprotein antibody associated disease (MOGAD)Myelin Oligodendrocyte Glycoprotein antibody associated disease (MOGAD)
Myelin Oligodendrocyte Glycoprotein antibody associated disease (MOGAD)MohamadAlhes
 
CEHPALOSPORINS.pptx By Harshvardhan Dev Bhoomi Uttarakhand University
CEHPALOSPORINS.pptx By Harshvardhan Dev Bhoomi Uttarakhand UniversityCEHPALOSPORINS.pptx By Harshvardhan Dev Bhoomi Uttarakhand University
CEHPALOSPORINS.pptx By Harshvardhan Dev Bhoomi Uttarakhand UniversityHarshChauhan475104
 
The next social challenge to public health: the information environment.pptx
The next social challenge to public health:  the information environment.pptxThe next social challenge to public health:  the information environment.pptx
The next social challenge to public health: the information environment.pptxTina Purnat
 
medico legal aspects of wound - forensic medicine
medico legal aspects of wound - forensic medicinemedico legal aspects of wound - forensic medicine
medico legal aspects of wound - forensic medicinethanaram patel
 
Informed Consent Empowering Healthcare Decision-Making.pptx
Informed Consent Empowering Healthcare Decision-Making.pptxInformed Consent Empowering Healthcare Decision-Making.pptx
Informed Consent Empowering Healthcare Decision-Making.pptxSasikiranMarri
 
Introduction to Sports Injuries by- Dr. Anjali Rai
Introduction to Sports Injuries by- Dr. Anjali RaiIntroduction to Sports Injuries by- Dr. Anjali Rai
Introduction to Sports Injuries by- Dr. Anjali RaiGoogle
 
History and Development of Pharmacovigilence.pdf
History and Development of Pharmacovigilence.pdfHistory and Development of Pharmacovigilence.pdf
History and Development of Pharmacovigilence.pdfSasikiranMarri
 
Tans femoral Amputee : Prosthetics Knee Joints.pptx
Tans femoral Amputee : Prosthetics Knee Joints.pptxTans femoral Amputee : Prosthetics Knee Joints.pptx
Tans femoral Amputee : Prosthetics Knee Joints.pptxKezaiah S
 

Último (20)

Music Therapy's Impact in Palliative Care| IAPCON2024| Dr. Tara Rajendran
Music Therapy's Impact in Palliative Care| IAPCON2024| Dr. Tara RajendranMusic Therapy's Impact in Palliative Care| IAPCON2024| Dr. Tara Rajendran
Music Therapy's Impact in Palliative Care| IAPCON2024| Dr. Tara Rajendran
 
Nutrition of OCD for my Nutritional Neuroscience Class
Nutrition of OCD for my Nutritional Neuroscience ClassNutrition of OCD for my Nutritional Neuroscience Class
Nutrition of OCD for my Nutritional Neuroscience Class
 
Radiation Dosimetry Parameters and Isodose Curves.pptx
Radiation Dosimetry Parameters and Isodose Curves.pptxRadiation Dosimetry Parameters and Isodose Curves.pptx
Radiation Dosimetry Parameters and Isodose Curves.pptx
 
VarSeq 2.6.0: Advancing Pharmacogenomics and Genomic Analysis
VarSeq 2.6.0: Advancing Pharmacogenomics and Genomic AnalysisVarSeq 2.6.0: Advancing Pharmacogenomics and Genomic Analysis
VarSeq 2.6.0: Advancing Pharmacogenomics and Genomic Analysis
 
PHYSIOTHERAPY IN HEART TRANSPLANTATION..
PHYSIOTHERAPY IN HEART TRANSPLANTATION..PHYSIOTHERAPY IN HEART TRANSPLANTATION..
PHYSIOTHERAPY IN HEART TRANSPLANTATION..
 
Study on the Impact of FOCUS-PDCA Management Model on the Disinfection Qualit...
Study on the Impact of FOCUS-PDCA Management Model on the Disinfection Qualit...Study on the Impact of FOCUS-PDCA Management Model on the Disinfection Qualit...
Study on the Impact of FOCUS-PDCA Management Model on the Disinfection Qualit...
 
epilepsy and status epilepticus for undergraduate.pptx
epilepsy and status epilepticus  for undergraduate.pptxepilepsy and status epilepticus  for undergraduate.pptx
epilepsy and status epilepticus for undergraduate.pptx
 
CCSC6142 Week 3 Research ethics - Long Hoang.pdf
CCSC6142 Week 3 Research ethics - Long Hoang.pdfCCSC6142 Week 3 Research ethics - Long Hoang.pdf
CCSC6142 Week 3 Research ethics - Long Hoang.pdf
 
Phytochemical Investigation of Drugs PDF.pdf
Phytochemical Investigation of Drugs PDF.pdfPhytochemical Investigation of Drugs PDF.pdf
Phytochemical Investigation of Drugs PDF.pdf
 
LESSON PLAN ON fever.pdf child health nursing
LESSON PLAN ON fever.pdf child health nursingLESSON PLAN ON fever.pdf child health nursing
LESSON PLAN ON fever.pdf child health nursing
 
METHODS OF ACQUIRING KNOWLEDGE IN NURSING.pptx by navdeep kaur
METHODS OF ACQUIRING KNOWLEDGE IN NURSING.pptx by navdeep kaurMETHODS OF ACQUIRING KNOWLEDGE IN NURSING.pptx by navdeep kaur
METHODS OF ACQUIRING KNOWLEDGE IN NURSING.pptx by navdeep kaur
 
Wessex Health Partners Wessex Integrated Care, Population Health, Research & ...
Wessex Health Partners Wessex Integrated Care, Population Health, Research & ...Wessex Health Partners Wessex Integrated Care, Population Health, Research & ...
Wessex Health Partners Wessex Integrated Care, Population Health, Research & ...
 
Myelin Oligodendrocyte Glycoprotein antibody associated disease (MOGAD)
Myelin Oligodendrocyte Glycoprotein antibody associated disease (MOGAD)Myelin Oligodendrocyte Glycoprotein antibody associated disease (MOGAD)
Myelin Oligodendrocyte Glycoprotein antibody associated disease (MOGAD)
 
CEHPALOSPORINS.pptx By Harshvardhan Dev Bhoomi Uttarakhand University
CEHPALOSPORINS.pptx By Harshvardhan Dev Bhoomi Uttarakhand UniversityCEHPALOSPORINS.pptx By Harshvardhan Dev Bhoomi Uttarakhand University
CEHPALOSPORINS.pptx By Harshvardhan Dev Bhoomi Uttarakhand University
 
The next social challenge to public health: the information environment.pptx
The next social challenge to public health:  the information environment.pptxThe next social challenge to public health:  the information environment.pptx
The next social challenge to public health: the information environment.pptx
 
medico legal aspects of wound - forensic medicine
medico legal aspects of wound - forensic medicinemedico legal aspects of wound - forensic medicine
medico legal aspects of wound - forensic medicine
 
Informed Consent Empowering Healthcare Decision-Making.pptx
Informed Consent Empowering Healthcare Decision-Making.pptxInformed Consent Empowering Healthcare Decision-Making.pptx
Informed Consent Empowering Healthcare Decision-Making.pptx
 
Introduction to Sports Injuries by- Dr. Anjali Rai
Introduction to Sports Injuries by- Dr. Anjali RaiIntroduction to Sports Injuries by- Dr. Anjali Rai
Introduction to Sports Injuries by- Dr. Anjali Rai
 
History and Development of Pharmacovigilence.pdf
History and Development of Pharmacovigilence.pdfHistory and Development of Pharmacovigilence.pdf
History and Development of Pharmacovigilence.pdf
 
Tans femoral Amputee : Prosthetics Knee Joints.pptx
Tans femoral Amputee : Prosthetics Knee Joints.pptxTans femoral Amputee : Prosthetics Knee Joints.pptx
Tans femoral Amputee : Prosthetics Knee Joints.pptx
 

Antiemetics

  • 1. Antinauseants & Antiemetic Agents Brian J. Piper, Ph.D., M.S. October 16, 2012
  • 2. Learning objectives Pharmacy students should be able to: 1. Explain emesis pathway(s) 2. Identify drug targets for antiemetic agents 3. Describe mechanism of action of antiemetic agents 4. Recognize adverse effects of antiemetic agents Ibn Bultan (1531)
  • 3. Emesis • A protective reflex that serves to rid the stomach and intestine of toxic substances and prevent their further ingestion. • Vomiting is a complex process that consists of: – Pre-ejection phase: gastric relaxation & retroperistalsis – Retching: rhythmic action of respiratory muscles preceding vomiting and consisting of contraction of abdominal and intercostal muscles and diaphragm against a closed glottis – Ejection: intense contraction of the abdominal muscles and relaxation of the upper esophageal sphincter
  • 4. Importance • Vomiting is an adverse effect of many clinically useful drugs: – cancer chemotherapy & radiation – opioids – general anesthetics • Nausea may be a component of: – migraines – pregnancy
  • 5. Area Postrema • surrounds 4th ventricle • outside blood brain barrier & monitors blood Miller & Leslie (1994). Frontiers in Neuroendocrinology, 15(4), 301-320.
  • 6. Activity of Area Postrema Following Chemotherapy Neuronal activation (c-fos, arrowheads) in the area postrema (AP) following cisplatin administration (10 mg/kg) to an adult ferret. CC: Central Canal (4th ventricle); NTS: nucleus of the solitary tract; DMX dorsal motor nucleus of vagus nerve. Miller & Leslie (1994). Frontiers in Neuroendocrinology, 15(4), 301-320.
  • 7. Area Postrema & Nausea • Rats (non-retching) got saccharine, injection (saline or lithium chloride), then two-bottle choice Bernstein et al. (1992). Brain Research, 575, 132-137.
  • 8. Area Postrema & Nausea • Rats (non-retching) got saccharine, injection (saline or lithium chloride), then two-bottle choice • Lesion of the area postrema eliminated this response. Bernstein et al. (1992). Brain Research, 575, 132-137.
  • 9. Area Postrema (AP) & Nausea * * • Rats (+AP lesioned) got saccharine, injection (saline or lithium chloride) • Behavioral ratings of response to lithium (Lieing on Belly) were made • Pre-inections, a meal was consumed. Stomach contents were examined. • Area Postrema = chemoreceptor trigger zone Bernstein et al. (1992). Brain Research, 575, 132-137.
  • 10. Anatomy of Emesis • Chemoreceptor trigger zone (CTZ) in the area postrema (AP) at the bottom of the fourth ventricle has high concentration of: • 5-HT3 (?) • D2 • M1 • NK1 • opioid • The CTZ has connections to the Nucleus of the Tractus Solitarius (NTS) & Reticular Formation (aka vomiting center) which contains: • 5-HT3 (?) • M1 • NK1
  • 11. M1 D2 Krakauer et al. (2005). New England Journal of Medicine, 352, 817.
  • 12. Classification of antiemetics † some peripheral activity at 5-HT3 receptor; ‡ some antihistamine and anticholinergic activity
  • 13. Ondansetron • MOA: 5-HT3 antagonist • Indications: radiation, chemotherapy, postoperapative • Dosing: 1x/day • Adverse Effects: constipation & headache
  • 14. 5-HT3 Antagonists (-etron) Compared Granisetron Ondansetron Dolasetron Brand name Kytril, Sancuso Zofran Anzemet FDA Approval 1988 1991G 1997 Indications chemotherapy chemotherapy chemotherapy radiation radiation radiation Half-life (hours) 9 4 8 Routes of oral, iv, transdermal oral, iv oral, iv administration Adverse effects constipation & constipation & headache headaches headaches tachy/bradycardia Ggeneric form available
  • 15. 5-HT3 Antagonists (-etron) Compared Granisetron Ondansetron Palonosetron Brand name Kytril, Sancuso Zofran Aloxi FDA Approval 1988 1991G 2003 (delayed nausea) Indications chemotherapy chemotherapy chemotherapy radiation radiation post-operative Half-life (hours) 10 4 40 Routes of oral, iv, transderm oral, iv oral, iv administration Adverse effects constipation & constipation & headache, constipation, headaches headaches QT
  • 16. 5-HT3 Antagonists Compared: Efficacy • Chemotherapy patients (N = 563) randomized to receive ondansetron versus palonosetron • Treatment failure = emetic response or rescue medication % of Patients Gralla et al. (2003). Annals of Oncology, 14, 1570-1577.
  • 17. 5-HT3 Antagonists Compared: Safety • Chemotherapy patients (N = 563) randomized to receive ondansetron versus palonosetron Gralla et al. (2003). Annals of Oncology, 14, 1570-1577.
  • 18. Pathway of Emesis 4 3 1 5 2
  • 19. Pavlov’s Experiments During conditioning, the neutral stimulus (tone) and the US (food) are paired, resulting in salivation (UR). After conditioning, the neutral stimulus (now Conditioned Stimulus, CS) elicits salivation (now Conditioned Response, CR) 19
  • 20. Classical Conditioning & Nausea • Pre-Conditioning – Neutral Stimulus: hospital environment – Unconditioned Stimulus: chemotherapy – Unconditioned Response: nausea & vomiting • Post-Conditioning – Conditioned Stimulus: hospital environment – Conditioned Response: nausea & vomiting
  • 21. Metoclopramide • MOA: D2 antagonist, 5-HT3 antagonist • Indications: chemotherapy, post-operative • Adverse Effects: restlessness, Parkinsonian symptoms 1 min: http://www.youtube.com/watch?v=dum81RdFrhM Pronunciation: http://dictionary.reference.com/browse/metoclopramide?s=t
  • 22. Olanzapine • MOA: D2 antagonist + others • Indications: acute & delayed CINV • Adverse Effects: Stahl (2008). Essential Psychopharmacology, p. 411.
  • 23. Dronabinol • Synthetic delta-9-tetrahydrocannabinol (Δ9-THC) • Schedule: III • MOA: Cannabinoid receptors? • AE: dysphoria, postural hypotension
  • 24. Density of Cannabinoid Receptor 1 (Increased Darkness = more receptors labeled with [3H]CP-55,940) Hekenham et al. (1991) J Neurosci, 11, 563-583.
  • 25. Aprepitant MOA: substance P binds to NeurokininA receptors Arg-Pro-Lys-Pro-Gln-Gln-Phe-Phe-Gly-Leu-Met NeurokininA antagonist Indications: CINV, PONV Adverse Effects: asthenia, constipation, hiccups
  • 26. NeurokininA Antagonist: Efficacy • Abdominal surgery patients (N=750) randomized to receive oral Aprepitant or Ondansetron • Hours until vomiting or rescue medication Gan et al. (2007). Anesthesia & Analgesia, 104(5), 1082-1089.
  • 27. NeurokininA Antagonist: Safety • Abdominal surgery patients (N=750) randomized to receive oral Aprepitant or Ondansetron Gan et al. (2007). Anesthesia & Analgesia, 104(5), 1082-1089.
  • 28.
  • 29. Summary • High Therapeutic Index • Low Therapeutic Index – 5-HT3 antagonists – cannabinoids – NK1 antagonists – dopamine antagonists – corticosteroids (combo) – benzodiazepines Hesketh (2008). New England Journal of Medicine, 358, 2482-2494.
  • 30. Abbreviations CB1 Cannabinoid 1 CINV Chemotherapy-induced nausea and vomiting CTZ Chemoreceptor trigger zone DA Dopamine NK1 Neurokinin 1 PONV Post-operative nausea and vomiting STN Solitary tract nucleus VC Vomiting center

Notas do Editor

  1. Source of painting unknown (Wikipedia)
  2. Left: 14th century illustration of vomiting from the CasanatenseTacuinumSanitatis,a medieval handbook on health and wellbeing written in Baghdad. 
  3. Emesis is the medical name for vomiting, throwing-up, retching, and puking. This can be a life-saving event (think alcohol poisoning). This may or may not be preceded by nausea.
  4. A young, medically qualified patient being treated by combination chemotherapy for sarcoma stated that “the severity of vomiting at time made the thought of death seem like a welcome relief”. Lower right shows offspring of mothers that received thalidomide to treat their morning sickness.
  5. There are just a few areas that are outside the BBB (pineal, posterior pituitary, and structures adjacent to the 3rd & 4th ventricles). The area postrema is located adjacent to the most caudal end of the 4th ventricle.
  6. The ferret vomited 1.5 hours after chemo administration.
  7. Two bottle choice involves saccharine solution versus water.
  8. 5-HT3 receptor is present in both the CTZ & NTS but it is unclear if these have an effect on vomiting.
  9. Vomiting consists of voluntary (cortex) and involuntary (medulla) components. Vestibular system connects of vomiting center via 8th cranial nerve.
  10. Pronounced: on dance ah tron; often combined with dexamethasone (the mechanism for corticosteroid increase in effectiveness of 5-HT3 antagonists is unknown, adverse effects are relatively rare
  11. Half-life following oral administration. >90% of serotonin in body is found in GI tract so constipation should come as no surprise with 5-HT3 antagonists. Dolasetron may prolong QT interval so avoid with patients born with congenital long QT syndrome or taking medications that prolong QT (e.g. epinephrine, amitryptyline). These 3 1st generation 5-HT3 antagonists produce largely equivalent effects.
  12. Palonosetron has exceptional binding to 5-HT3 and a very long-half life. This is useful as some chemos produce both an acute and delayed nausea. Adverse effects include prolongation of the QT interval.
  13. The majority of patients were breast cancer (57%) and the most common chemo was cyclophosphamide (63%). No prophylactic corticosteroids were used.
  14. These are adverse events that are believed to be unrelated to the chemotherapy.
  15. Benzodiazepines can be quite helpful for anticipatory nausea.
  16. Pronunciation:met-oh-klO-pruh-mahyd; also used as a gastroprokinetic as this will stimulate stomach emptying; may also cause dystonias
  17. Olanzapine is an atypical anti-psychotic that acts to block D2 > 5-HT2A >5-HT3, antihistamine.
  18. Pronunciation: (ap-RE-pi-tant). Substance P is a peptide composed of 11 amino acids and is released following pain. Asthenia (as-thee-nee-uh) is weakness. Fosaprepitant is a prodrug.
  19. Although studied here individually, when used for CINV,Aprepitant is often combined with 5-HT3 antagonists and corticosteriods. Note that nausea is listed here but all patients are post-operative.